Developer docs
API playgroundTry for free, no card

Search company profiles

DecisionRx

Full company profile

uuid000222d

Namestring
DecisionRx
Legal namestring
DecisionRx, Inc.
Websiteurl
decisionrx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

DecisionRx, Inc. is a value-based healthcare services company founded in 2022 and headquartered in Dover, Delaware with primary operations in Indianapolis. The company operates a Medication Therapy Optimization (MTO) platform that combines pharmacogenomics (PGx) testing, clinical pharmacist expertise, and proprietary medication risk stratification to help prescribers select and dose medications more effectively. The platform assigns medication failure risk scores using drug interactions, contraindications, side effects, adverse events, FDA warnings, and pharmacogenomic data, then routes high-risk patients to specialized clinical pharmacists for comprehensive medication review. Outputs include a personalized Medication Action Proposal and a pharmacogenomics report covering over 200 prescription drugs, delivered to prescribers for incorporation into existing clinical workflows.

The company serves Medicare Advantage Plans, Accountable Care Organizations, self-insured employers, pharmacy benefit facilitators, and individual self-pay consumers. Under its value-based care model, DecisionRx bears the full cost of lab testing and pharmacist reviews, aligning its revenue to demonstrated healthcare cost savings of approximately $3,600 per Medicare patient per year and $1,200 for patients under 65, and achieving reported 8-12% total cost savings, 6.8% reduction in ER visits, and 14.9% reduction in inpatient days. Distribution combines enterprise field sales (led by Chief Growth Officer Michael Tilton, former Humana SVP) with channel partnerships across AmeriLife, Imperium Health, MotivHealth, Beanstalk Benefits, and BeneCard PBF, plus a $495 direct-to-consumer PGx kit.

DecisionRx is privately held, with a $100 million credit facility from The Carlyle Group (January 2024) that includes an option for Carlyle to acquire 25% of equity. The credit facility is sized to fund MTO for over 100,000 patients. The company operates with 11-50 employees, has been recognized as a 2024 Fierce Healthcare Innovation Awards finalist, and has assembled a clinical advisory board including former U.S. Secretary of Veterans Affairs David Shulkin, MD, and Beth Israel Lahey Health EVP/CCO Rob Fields, MD.

Short descriptiontext

DecisionRx is a value-based healthcare services company whose Medication Therapy Optimization platform combines pharmacogenomics testing, proprietary risk stratification, and clinical pharmacist reviews to reduce medication failure for Medicare Advantage plans, ACOs, self-insured employers, and self-pay consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDover, United States
HQ citystring
Dover
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medication therapy optimization, pharmacogenomics testing, value-based care, medication risk management, clinical pharmacy services
Industry4 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAL
Medication Analytics, Outcomes & Cost Optimization
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Medication Therapy Optimization / Healthcare Technology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Value-Based Care Contracts with Payers
TypeUsage Based
Description

DecisionRx generates revenue through value-based care contracts with Medicare Advantage Plans, Accountable Care Organizations (ACOs), and self-insured employers. The company bears the full cost of delivering Medication Therapy Optimization services and generates savings from reduced medication failures, hospitalizations, and emergency department visits. Clinical pharmacists make personalized medication recommendations to prescribers, with financial outcomes tied to measurable improvements in health and cost reduction.

decisionrx.com
2Direct-to-Consumer PGx Testing
TypeOne Time License
Description

Individual consumers can purchase pharmacogenomics testing kits directly at $495 per kit, with HSA/FSA acceptance. Includes Medication Action Proposal, Comprehensive PGx Report covering 200+ prescription drugs, and free pharmacist consultation for up to 1 year.

decisionrx.com
3Partnership with Pharmacy Benefit Facilitators
TypeUsage Based
Description

Partnership with BeneCard PBF to deliver personalized, data-driven medication insights to clients and members nationwide. Offers value-based and risk-share options for plan sponsors, with financial incentives tied to measurable improvements in health outcomes and cost savings.

decisionrx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Self-pay consumer PGx testing kit
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$495 per kit including Medication Action Proposal, Comprehensive Pharmacogenomics Report covering 200+ prescription drugs, and free pharmacist consultation for up to 1 year. HSA/FSA accepted.

decisionrx.com
2Health plan / payer sponsored MTO
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

No cost to patients whose health plans cover the benefit. DecisionRx bears full cost of implementation and generates revenue from healthcare cost savings ($3,600 per Medicare patient per year, $1,200 for under-65 patients).

decisionrx.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

DecisionRx sells a Medication Therapy Optimization (MTO) platform that combines pharmacogenomics testing, clinical history and medical claims analysis, and comprehensive medication reviews by specialized clinical pharmacists to help prescribers select the right medications for each individual patient. Under a value-based care model, DecisionRx bears the full cost of MTO implementation and recoups revenue from healthcare cost savings shared with Medicare Advantage Plans, Accountable Care Organizations, and self-insured employers. The company also sells a direct-to-consumer PGx testing kit at $495 with a Medication Action Proposal and pharmacist consultation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces total annualized healthcare costs by over $3,600 per Medicare patient per year
+6 more records
Product overview1 text field

DecisionRx offers a unified Medication Therapy Optimization (MTO) platform supplemented by a direct-to-consumer DecisionRx Kit product. The core MTO platform leverages proprietary medication risk stratification, pharmacogenomics testing, clinical history analysis, and comprehensive medication reviews by specialized pharmacists to optimize prescribing decisions. The companion DecisionRx Kit ($495) provides individual consumers with PGx testing, a Medication Action Proposal, and a pharmacogenomics report covering over 200 prescription drugs, with free pharmacist consultation. Both products work in concert to deliver personalized medication optimization informed by genetics and clinical data science.

Product and service2 records
1Medication Therapy Optimization (MTO) Platform
2DecisionRx Kit (Direct-to-Consumer PGx Testing)
CategoryPharmacogenomics Testing Kit / Direct-to-Consumer Diagnostic
Description

A consumer-facing pharmacogenomics (PGx) testing kit priced at $495 (HSA/FSA accepted) that includes a cheek-swab test, a personalized Medication Action Proposal, a comprehensive PGx report covering over 200 prescription drugs, and free pharmacist consultation for up to 1 year. Available directly to individual consumers at decisionrx.com/purchase.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-29
Description

DecisionRx partnered with BeneCard PBF, the original Pharmacy Benefit Facilitator, to bring personalized medication insights to BeneCard PBF's clients and members nationwide. The partnership combines DecisionRx's pharmacogenomics and analytics platform with BeneCard's transparent, outcomes-focused PBF model. Both organizations will offer value-based and risk-share options for plan sponsors including union health funds and self-insured employers.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-07-17
Description

DecisionRx partnered with MedeAnalytics to power value-based medication optimization. MedeAnalytics' Health Fabric platform expands DecisionRx's ability to quantify and communicate clinical and economic impact under value-based care contracts. The partnership enables ROI quantification, cost savings tracking, performance measurement on quality metrics, and seamless integration with payer and provider stakeholders.

Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-04-01
Description

Philadelphia-based Beanstalk Benefits partnered with DecisionRx to offer MTO to their benefit platform members. Beanstalk offers 40+ services allowing employers of any size to access benefit resources under a single contract. The partnership targets employers with under 5,000 employees and freelance/independent contractors.

Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2024-10-10
Description

MotivHealth, a Utah-based health insurer focused on HSA-based plans, partnered with DecisionRx to offer the MTO program to select members. MotivHealth is revolutionizing health insurance by focusing on HSA-based plans that produce lower premiums and improved wellness. Both companies share a goal of improving wellness and eliminating wasted healthcare expense.

5AmeriLife Group
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-07-18
Description

DecisionRx partnered with AmeriLife to provide Medicare Advantage and Medicare Supplement patients access to its MTO platform. AmeriLife's extensive health distribution platform and commitment to quality, technology-driven healthcare solutions enables expansion of DecisionRx's MTO impact. The collaboration integrates comprehensive medication review into AmeriLife's Medicare products.

decisionrx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-11
Description

Imperium Health, a pioneer in creating and managing ACOs and value-based care programs, partnered with DecisionRx to deliver MTO to Medicare beneficiaries in its ACOs. A successful pilot demonstrated 78% of patients received clinically actionable medication guidance. Imperium Health organizes and manages partnerships with providers and ACOs supporting clinical and financial performance improvement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Myriad Genetics offers GeneSight, a pharmacogenomic test that informs prescribing decisions for mental health medications. It is one of the most established PGx decision-support products and competes most directly with DecisionRx's pharmacogenomics-driven Medication Action Proposal.

TypeDirect peer
Description

Genomind provides a pharmacogenomic testing and clinical decision support platform focused on mental health prescribing, with similar clinical pharmacist consultation components. Its specialty-PGx model overlaps closely with DecisionRx's MTO offering for poly-pharmacy patients.

TypeDirect peer
Description

Tabula Rasa (now part of CarelonRx) delivers medication therapy management, risk stratification, and pharmacist-led medication safety services to health plans and PACE programs. Its MTM and pharmacogenomics-informed medication optimization directly parallel DecisionRx's MTO value-based contracts.

TypeDirect peer
Description

Coriell Life Sciences offers pharmacogenomic testing and a clinical decision support tool (GeneDose) used by providers to personalize medication selection. It targets similar provider and payer populations as DecisionRx's PGx-enabled MTO platform.

TypeDirect peer
Description

YouScript delivers pharmacogenomics decision support integrated into EHR workflows for prescribers. It competes with DecisionRx's prescriber-facing PGx and clinical pharmacist workflow at the point of prescribing.

TypeDirect peer
Description

RxAnte provides analytics and intervention services that improve medication adherence and appropriate utilization for health plans, with a similar value-based alignment to payers as DecisionRx's MTO. Both operate within the medication optimization and outcomes space for at-risk populations.

TypeOthers
Description

hc1 Insights is a precision health analytics platform founded by DecisionRx's Executive Chairman Brad Bostic. While not a direct competitor, it is closely related through shared leadership and overlapping analytics capabilities for healthcare organizations.

TypeBroad incumbent
Description

MedImpact is a large independent pharmacy benefit manager with medication therapy management and clinical programs for health plan clients. It is a broader incumbent offering medication optimization as part of a full PBM portfolio, in contrast to DecisionRx's focused MTO offering delivered through partners like BeneCard PBF.

TypeOthers
Description

BeneCard PBF is a pharmacy benefit facilitator and partner that distributes DecisionRx's MTO program to its self-insured employer and union health fund clients. It is an ecosystem partner rather than a direct competitor, but operates adjacent medication management services.

TypeBroad incumbent
Description

Quest Diagnostics is a major clinical laboratory that offers pharmacogenomic testing services and broader medication-related diagnostics. DecisionRx's Clinical Advisor Steven Goldberg, MD is Quest's Chief Health Officer. As a broad incumbent, Quest overlaps in lab infrastructure but not in DecisionRx's clinical pharmacist-led, value-based delivery model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DecisionRx

Medication Therapy Optimization / Healthcare Technologydecisionrx.com

DecisionRx is a value-based healthcare services company whose Medication Therapy Optimization platform combines pharmacogenomics testing, proprietary risk stratification, and clinical pharmacist reviews to reduce medication failure for Medicare Advantage plans, ACOs, self-insured employers, and self-pay consumers.

What DecisionRx does

DecisionRx, Inc. is a value-based healthcare services company founded in 2022 and headquartered in Dover, Delaware with primary operations in Indianapolis. The company operates a Medication Therapy Optimization (MTO) platform that combines pharmacogenomics (PGx) testing, clinical pharmacist expertise, and proprietary medication risk stratification to help prescribers select and dose medications more effectively. The platform assigns medication failure risk scores using drug interactions, contraindications, side effects, adverse events, FDA warnings, and pharmacogenomic data, then routes high-risk patients to specialized clinical pharmacists for comprehensive medication review. Outputs include a personalized Medication Action Proposal and a pharmacogenomics report covering over 200 prescription drugs, delivered to prescribers for incorporation into existing clinical workflows.

The company serves Medicare Advantage Plans, Accountable Care Organizations, self-insured employers, pharmacy benefit facilitators, and individual self-pay consumers. Under its value-based care model, DecisionRx bears the full cost of lab testing and pharmacist reviews, aligning its revenue to demonstrated healthcare cost savings of approximately $3,600 per Medicare patient per year and $1,200 for patients under 65, and achieving reported 8-12% total cost savings, 6.8% reduction in ER visits, and 14.9% reduction in inpatient days. Distribution combines enterprise field sales (led by Chief Growth Officer Michael Tilton, former Humana SVP) with channel partnerships across AmeriLife, Imperium Health, MotivHealth, Beanstalk Benefits, and BeneCard PBF, plus a $495 direct-to-consumer PGx kit.

DecisionRx is privately held, with a $100 million credit facility from The Carlyle Group (January 2024) that includes an option for Carlyle to acquire 25% of equity. The credit facility is sized to fund MTO for over 100,000 patients. The company operates with 11-50 employees, has been recognized as a 2024 Fierce Healthcare Innovation Awards finalist, and has assembled a clinical advisory board including former U.S. Secretary of Veterans Affairs David Shulkin, MD, and Beth Israel Lahey Health EVP/CCO Rob Fields, MD.

DecisionRx firmographics

Firmographics
Name
DecisionRx
Legal name
DecisionRx, Inc.
Website
https://decisionrx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
DecisionRx is a value-based healthcare services company whose Medication Therapy Optimization platform combines pharmacogenomics testing, proprietary risk stratification, and clinical pharmacist reviews to reduce medication failure for Medicare Advantage plans, ACOs, self-insured employers, and self-pay consumers.
Ownership category
akta.pro rank

DecisionRx industry classification

Industry
Product category
Medication Therapy Optimization / Healthcare Technology
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAL
Medication Analytics, Outcomes & Cost Optimization
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Medication therapy optimization
  • Pharmacogenomics testing
  • Value-based care
  • Medication risk management
  • Clinical pharmacy services

Where DecisionRx is headquartered

Location

Headquarters

HQ city
Dover
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DecisionRx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Value-Based Care Contracts with Payers: DecisionRx generates revenue through value-based care contracts with Medicare Advantage Plans, Accountable Care Organizations (ACOs), and self-insured employers. The company bears the full cost of delivering Medication Therapy Optimization services and generates savings from reduced medication failures, hospitalizations, and emergency department visits. Clinical pharmacists make personalized medication recommendations to prescribers, with financial outcomes tied to measurable improvements in health and cost reduction.
  2. Direct-to-Consumer PGx Testing: Individual consumers can purchase pharmacogenomics testing kits directly at $495 per kit, with HSA/FSA acceptance. Includes Medication Action Proposal, Comprehensive PGx Report covering 200+ prescription drugs, and free pharmacist consultation for up to 1 year.
  3. Partnership with Pharmacy Benefit Facilitators: Partnership with BeneCard PBF to deliver personalized, data-driven medication insights to clients and members nationwide. Offers value-based and risk-share options for plan sponsors, with financial incentives tied to measurable improvements in health outcomes and cost savings.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goSelf-pay consumer PGx testing kit
Outcome Based/ PerformanceMulti-year contractHealth plan / payer sponsored MTO

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

DecisionRx product offering

Product offering

Core offering

DecisionRx sells a Medication Therapy Optimization (MTO) platform that combines pharmacogenomics testing, clinical history and medical claims analysis, and comprehensive medication reviews by specialized clinical pharmacists to help prescribers select the right medications for each individual patient. Under a value-based care model, DecisionRx bears the full cost of MTO implementation and recoups revenue from healthcare cost savings shared with Medicare Advantage Plans, Accountable Care Organizations, and self-insured employers. The company also sells a direct-to-consumer PGx testing kit at $495 with a Medication Action Proposal and pharmacist consultation.

Product overview

DecisionRx offers a unified Medication Therapy Optimization (MTO) platform supplemented by a direct-to-consumer DecisionRx Kit product. The core MTO platform leverages proprietary medication risk stratification, pharmacogenomics testing, clinical history analysis, and comprehensive medication reviews by specialized pharmacists to optimize prescribing decisions. The companion DecisionRx Kit ($495) provides individual consumers with PGx testing, a Medication Action Proposal, and a pharmacogenomics report covering over 200 prescription drugs, with free pharmacist consultation. Both products work in concert to deliver personalized medication optimization informed by genetics and clinical data science.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medication Therapy Optimization (MTO) Platform
  • DecisionRx Kit (Direct-to-Consumer PGx Testing) A consumer-facing pharmacogenomics (PGx) testing kit priced at $495 (HSA/FSA accepted) that includes a cheek-swab test, a personalized Medication Action Proposal, a comprehensive PGx report covering over 200 prescription drugs, and free pharmacist consultation for up to 1 year. Available directly to individual consumers at decisionrx.com/purchase.

Quantifiable outcome

  • Reduces total annualized healthcare costs by over $3,600 per Medicare patient per year
  • +6 more outcomes

Companies that use DecisionRx

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

DecisionRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

DecisionRx partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, strategic and major.

  • BeneCard PBFcoreStrategic or Co-development Partner · 29 July 2025DecisionRx partnered with BeneCard PBF, the original Pharmacy Benefit Facilitator, to bring personalized medication insights to BeneCard PBF's clients and members nationwide. The partnership combines DecisionRx's pharmacogenomics and analytics platform with BeneCard's transparent, outcomes-focused PBF model. Both organizations will offer value-based and risk-share options for plan sponsors including union health funds and self-insured employers.
  • MedeAnalyticsstrategicTechnology or Integration · 17 July 2025DecisionRx partnered with MedeAnalytics to power value-based medication optimization. MedeAnalytics' Health Fabric platform expands DecisionRx's ability to quantify and communicate clinical and economic impact under value-based care contracts. The partnership enables ROI quantification, cost savings tracking, performance measurement on quality metrics, and seamless integration with payer and provider stakeholders.
  • Beanstalk BenefitsmajorGTM or Marketing Partner · 1 April 2025Philadelphia-based Beanstalk Benefits partnered with DecisionRx to offer MTO to their benefit platform members. Beanstalk offers 40+ services allowing employers of any size to access benefit resources under a single contract. The partnership targets employers with under 5,000 employees and freelance/independent contractors.
  • MotivHealthmajorGTM or Marketing Partner · 10 October 2024MotivHealth, a Utah-based health insurer focused on HSA-based plans, partnered with DecisionRx to offer the MTO program to select members. MotivHealth is revolutionizing health insurance by focusing on HSA-based plans that produce lower premiums and improved wellness. Both companies share a goal of improving wellness and eliminating wasted healthcare expense.
  • AmeriLife GroupcoreGTM or Marketing Partner · 18 July 2024DecisionRx partnered with AmeriLife to provide Medicare Advantage and Medicare Supplement patients access to its MTO platform. AmeriLife's extensive health distribution platform and commitment to quality, technology-driven healthcare solutions enables expansion of DecisionRx's MTO impact. The collaboration integrates comprehensive medication review into AmeriLife's Medicare products.
  • Imperium HealthcoreStrategic or Co-development Partner · 11 June 2024Imperium Health, a pioneer in creating and managing ACOs and value-based care programs, partnered with DecisionRx to deliver MTO to Medicare beneficiaries in its ACOs. A successful pilot demonstrated 78% of patients received clinically actionable medication guidance. Imperium Health organizes and manages partnerships with providers and ACOs supporting clinical and financial performance improvement.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

DecisionRx competitors and assessment

Company assessment

Direct peers

  • Myriad Genetics (GeneSight): Myriad Genetics offers GeneSight, a pharmacogenomic test that informs prescribing decisions for mental health medications. It is one of the most established PGx decision-support products and competes most directly with DecisionRx's pharmacogenomics-driven Medication Action Proposal.
  • Genomind: Genomind provides a pharmacogenomic testing and clinical decision support platform focused on mental health prescribing, with similar clinical pharmacist consultation components. Its specialty-PGx model overlaps closely with DecisionRx's MTO offering for poly-pharmacy patients.
  • Tabula Rasa HealthCare (CarelonRx): Tabula Rasa (now part of CarelonRx) delivers medication therapy management, risk stratification, and pharmacist-led medication safety services to health plans and PACE programs. Its MTM and pharmacogenomics-informed medication optimization directly parallel DecisionRx's MTO value-based contracts.
  • Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic testing and a clinical decision support tool (GeneDose) used by providers to personalize medication selection. It targets similar provider and payer populations as DecisionRx's PGx-enabled MTO platform.
  • YouScript (Translational Software): YouScript delivers pharmacogenomics decision support integrated into EHR workflows for prescribers. It competes with DecisionRx's prescriber-facing PGx and clinical pharmacist workflow at the point of prescribing.
  • RxAnte: RxAnte provides analytics and intervention services that improve medication adherence and appropriate utilization for health plans, with a similar value-based alignment to payers as DecisionRx's MTO. Both operate within the medication optimization and outcomes space for at-risk populations.

Others

  • hc1 Insights: hc1 Insights is a precision health analytics platform founded by DecisionRx's Executive Chairman Brad Bostic. While not a direct competitor, it is closely related through shared leadership and overlapping analytics capabilities for healthcare organizations.
  • BeneCard PBF: BeneCard PBF is a pharmacy benefit facilitator and partner that distributes DecisionRx's MTO program to its self-insured employer and union health fund clients. It is an ecosystem partner rather than a direct competitor, but operates adjacent medication management services.

Broad incumbents

  • MedImpact Healthcare Systems: MedImpact is a large independent pharmacy benefit manager with medication therapy management and clinical programs for health plan clients. It is a broader incumbent offering medication optimization as part of a full PBM portfolio, in contrast to DecisionRx's focused MTO offering delivered through partners like BeneCard PBF.
  • Quest Diagnostics: Quest Diagnostics is a major clinical laboratory that offers pharmacogenomic testing services and broader medication-related diagnostics. DecisionRx's Clinical Advisor Steven Goldberg, MD is Quest's Chief Health Officer. As a broad incumbent, Quest overlaps in lab infrastructure but not in DecisionRx's clinical pharmacist-led, value-based delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DecisionRx social profiles

Digital presence

DecisionRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DecisionRx leadership team

Management profile

Number of profiles

Profiles11 records

DecisionRx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DecisionRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DecisionRx

What does DecisionRx do?

DecisionRx sells a Medication Therapy Optimization (MTO) platform that combines pharmacogenomics testing, clinical history and medical claims analysis, and comprehensive medication reviews by specialized clinical pharmacists to help prescribers select the right medications for each individual patient. Under a value-based care model, DecisionRx bears the full cost of MTO implementation and recoups revenue from healthcare cost savings shared with Medicare Advantage Plans, Accountable Care Organizations, and self-insured employers. The company also sells a direct-to-consumer PGx testing kit at $495 with a Medication Action Proposal and pharmacist consultation.

Is DecisionRx a public or private company?

DecisionRx is a private company. It is classified as venture growth investor backed and is currently operating.

When was DecisionRx founded?

DecisionRx was founded in 2022. It employs 11 to 50 people.

Where is DecisionRx based?

DecisionRx is headquartered in Dover, United States, in the North America region.

How does DecisionRx make money?

Three revenue lines are on record. Value-Based Care Contracts with Payers are the primary driver. The others are direct-to-Consumer PGx Testing and partnership with Pharmacy Benefit Facilitators.

Who are DecisionRx's main competitors?

Direct peers on record are Myriad Genetics (GeneSight), Genomind, Tabula Rasa HealthCare (CarelonRx), Coriell Life Sciences, YouScript (Translational Software) and RxAnte. Others are hc1 Insights and BeneCard PBF. Broad incumbents are MedImpact Healthcare Systems and Quest Diagnostics.

Does DecisionRx have an API?

No public API is recorded for DecisionRx.

What industry is DecisionRx in?

DecisionRx's product category is Medication Therapy Optimization / Healthcare Technology. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAL, Medication Analytics, Outcomes & Cost Optimization. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizJohns Hopkins Bloomberg School of Public Health Faculty Collaborate with DecisionRx to Advance Precision Medication Therapy OptimizationFaculty from the Johns Hopkins Bloomberg School of Public Health are collaborating with DecisionRx, a tech-enabled services company specializing in pharmacist-led medication surveillance and optimization, to generate real-world evidence supporting pharmacogenomics-guided medication management in value-based care. The research will leverage the Johns Hopkins ACG® System to evaluate the impact of PGx-guided medication therapy optimization on healthcare utilization, prescribing patterns, medication-related outcomes, and costs across patient populations with varying clinical complexity. The investigators aim to develop scalable, evidence-based approaches that integrate precision medicine, medication management, and advanced population health analytics to strengthen value-based care delivery and reimbursement models.Business Wire BlogDecisionRx, Inc. and BeneCard PBF Partner to Redefine Pharmacy Benefits Through Personalized Medication OptimizationDecisionRx, Inc. and BeneCard PBF announced a strategic partnership to integrate pharmacogenomics and medication therapy optimization into pharmacy benefits. The collaboration aims to reduce medication failure and generate savings, with DecisionRx's model lowering annual costs by about $3,600 per Medicare patient and $1,200 for under-65 enrollees.HIT ConsultantDecisionRx & MedeAnalytics Partner to Power Value-Based Medication OptimizationMedeAnalytics partnered with DecisionRx to integrate its Health Fabric analytics into DecisionRx's medication therapy optimization platform. The collaboration aims to quantify clinical and economic impact under value-based care contracts, citing potential savings of over $3,600 for Medicare patients and $1,200 for those under 65.YahooPartnership Uses Predictive Analytics to Address Medication FailureDecisionRx partnered with MedeAnalytics to use its Health Fabric analytics platform for medication therapy optimization. The partnership aims to quantify clinical and economic impact under value-based care contracts, with MTO reducing annual costs by over $3,600 for Medicare patients and $1,200 for those under 65.PR NewswirePartnership Uses Predictive Analytics to Address Medication FailureDecisionRx partnered with MedeAnalytics to use its Health Fabric analytics platform for medication therapy optimization. The partnership aims to quantify clinical and economic impact under value-based care contracts. DecisionRx's platform currently unlocks 8–12% in total healthcare cost savings for patients with high polypharmacy risk.MedeanalyticsDecisionRx Partners with MedeAnalytics to Power Value-Based Medication Optimization: Partnership Uses Predictive Analytics to Address Medication FailureMedeAnalytics and DecisionRx announced a strategic partnership to integrate MedeAnalytics' Health Fabric predictive analytics platform with DecisionRx's medication therapy optimization services. This collaboration aims to enhance the quantification of clinical and economic impacts for value-based care contracts, leveraging real-world data to track cost savings and performance metrics.YahooDecisionRx Appoints Health Insurance Executive Michael Tilton as Chief Growth OfficerDecisionRx appointed Michael Tilton as Chief Growth Officer to lead commercialization of its Medication Therapy Optimization platform. Tilton previously served as SVP at Humana, managing a portfolio with over $12.7 billion in annual revenue. The company cites medication failure accounts for at least 16% of total healthcare spending.YahooImperium Health, DecisionRx to Offer Free Medication Therapy OptimizationImperium Health and DecisionRx will offer free Medication Therapy Optimization to Medicare patients in Imperium's ACOs. An initial trial showed 78% of patients received actionable medication advice, with 53% needing changes and 70% having significant drug interactions. The program is estimated to create about $3,600 per engaged Medicare patient per year.Business Wire BlogImperium Health Partners With DecisionRx to Deliver No-Cost Medication Therapy Optimization to Medicare Beneficiaries Enrolled in its Accountable Care OrganizationsImperium Health partnered with DecisionRx to deliver medication therapy optimization to Medicare beneficiaries in its ACOs. In a pilot, 78% of patients received actionable guidance, and the platform saves over $3,600 per patient annually. The partnership aims to expand access across the Imperium network.Healthcare IT TodayDecisionRx Announces $100 Million Credit Facility with CarlyleDecisionRx announced a $100 million credit facility with Carlyle to fund its medication therapy optimization program. The financing will support lab testing and pharmacist reviews for over 100,000 patients, with the program reducing Medicare patient costs by over $3,600 annually. Carlyle received an option to acquire 25% of DecisionRx's equity.